Hilleman Laboratories developed affordable Haemophilus influenzae type b (Hib) vaccine
The new vaccine was also proved as 4 to 10 times more potent when compared to the existing licensed vaccines.
Hilleman Laboratories (HL), a global vaccine research and development organisation on 24 June 2015 announced the success of a preclinical trial conducted for Haemophilus influenzae type b (Hib) vaccine.
The research was published in the journal Vaccine.
The new vaccine formulation is expected to fill the immunization gap in the country as it is more cost effective and immunogenic compared to existing available vaccines.
The new vaccine was proved as 4 to 10 times more potent when compared to the existing licensed vaccines.
The Hib conjugate vaccine, which plays a vital role in national immunization programmes and also forms a main part of several mono-or multivalent vaccines for children, is the costliest component.
Hence, low cost of Hib makes a spectrum of vaccines more affordable and accessible even to the poor people in the country.
Hib is a deadly bacterium. It causes severe diseases like pneumonia and meningitis that are the leading causes of child deaths in India accounting for nearly 20 percent of the global deaths among children.
New Delhi based Hilleman Laboratories operates on a not-for-profit principle. It was formed as a partnership between global pharmaceutical organisation Merck & Co and the Wellcome Trust.
The UK based Wellcome Trust is a global charitable foundation dedicated to human and animal health. In the field of medical research, it is the world's second-largest private funder after the Bill & Melinda Gates Foundation.
Now get latest Current Affairs on mobile, Download # 1 Current Affairs App